Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

The new vaccine is an updated version of Moderna's widely-use Spikevax vaccine, which includes sequences from the original Wuhan strain of SARS-CoV-2, as well as from the Omicron BA.1 subvariant.

The phase 2 trial will test a 30 µg dose of the shot ... Clinical data show strong neutralising antibody responses against Omicron BA.1, but with less activity against the fast-emerging BA.

Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc Padmanabh Chivukula ...

Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the ...

Researchers at Kumamoto University have made a significant breakthrough in the fight against COVID-19 with the development of ...

The XBB.1.5 subvariant — nicknamed ‘Kraken’ — is arguably the most genetically rich and most transmissible SARS-CoV-2 omicron subvariant yet. News Wrap: Russia shells Bakhmut in eastern ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...